What Will The Global Biopharmaceutical Industry Look Like In 2027: Trendsetter Series Part 4 of 4
By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
From The December 2016 Issue
What 13 Life Science Trendsetters Expect For 2017 And Beyond
When Life Science Leader magazine sought executive-level participation for the signature 2017 Outlook issue published in December 2016, the response was overwhelming. This year’s feature article involved 13 executive life science leaders! The challenge such a situation creates is where to publish all of this wisdom. The solution we came up with was to create four Cutting Room Floor articles. In part four of this series we pose the question, “Looking even further ahead, what is your vision for how the global biopharmaceutical industry might look in the year 2027?” We hope you enjoy this supplement to the Life Science Leader magazine’s December 2016 cover feature.
Looking even further ahead, what is your vision for how the global biopharmaceutical industry might look in the year 2027?
Mark Alles, CEO, Celgene
When we reach the year 2027, I believe we will look back in time and see a curve of progress in cancer similar to what has been realized the past two decades with highly active antiretroviral treatments (HAART) for patients with HIV/AIDS. But for this opportunity to be realized we must increase investments in scientific research, particularly in rare diseases, and address barriers to patient access and data sharing that are impeding new discoveries. With a stronger ecosystem for R&D, more pro-patient and pro-innovation public policies, I believe the biopharmaceutical industry, along with its advocacy and academic partners, will turn significantly more acute diseases into chronic conditions, and many more chronic conditions will be cured by 2027.
Christopher P. Austin, M.D., Director, National Center for Advancing Translational Sciences (NCATS) at the NIH
A program I hope will make an impact prior to 2027 is our latest signature initiative: The NCATS Biomedical Data Translator program, “Translator” for short. One of the roadblocks to translation is the siloed nature of biomedical research data across diseases and disciplines which impedes discovery of commonalities across diseases and the teamwork required for successful translation. The ultimate vision for Translator is as an informatics platform that enables interrogation of relationships across the full spectrum of data types (i.e., from disease names, clinical signs and symptoms, to organ and cell pathology, genomics, and drug effects). Translator is an unprecedented effort to push beyond the “business-as-usual” incremental approach to translational science and bring about high-impact change.
John Maraganore, Ph.D., CEO and Board of Director Member, Alnylam Pharmaceuticals
We live an amazing period where the pace of biomedical discovery is unparalleled. I have no doubt that this will continue for the foreseeable future, creating boundless opportunities for new medicines. Our biopharma industry will play a central role in bringing this innovation to patients, and this will be very clear in 2027. I imagine we’ll see new medicines for many rare and common diseases, including Alzheimer’s, and that major advances in oncology will be achieved. By 2027, I believe that most hematologic malignancies will be curable. Given these opportunities our industry will be very strong. Biotech will continue to lead the advancement of the most transformative medicines for our industry.
In case you missed it, here are links to:
What Trends Will Have The Biggest Impact On Biopharma In 2017: Trendsetter Series Part 1 of 4
How Biopharmas Are Addressing Key Trends For 2017: Trendsetter Series Part 2 of 4
Shire CEO and Novartis CMO Weigh In On Trends For 2017: Trendsetter Series Part 3 of 4